用于特发性肾病综合征的抗CD20单克隆抗体：进展、挑战及未来方向 - Suppr

Suppr

超能文献

Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions.

作者信息

Angeletti Andrea, Ghiggeri Gian Marco

机构信息

Nephrology, Dialysis, and Transplantation, IRCCS Istituto Giannina Gaslini, Via Gaslini 6, Genoa, Italy.

出版信息

Pediatr Nephrol. 2025 May 1. doi: 10.1007/s00467-025-06738-w.

DOI:10.1007/s00467-025-06738-w

PMID:40310480

Abstract

摘要

相似文献

Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions.用于特发性肾病综合征的抗CD20单克隆抗体：进展、挑战及未来方向

Pediatr Nephrol. 2025 May 1. doi: 10.1007/s00467-025-06738-w.

Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.抗CD20抗体用于儿童特发性肾病综合征

Clin J Am Soc Nephrol. 2016 Apr 7;11(4):710-20. doi: 10.2215/CJN.08500815. Epub 2015 Nov 19.

Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.人源化或嵌合型抗 CD20 单克隆抗体治疗儿童肾病综合征：一项优效性随机临床试验。

J Am Soc Nephrol. 2021 Oct;32(10):2652-2663. doi: 10.1681/ASN.2021040561. Epub 2021 Sep 20.

Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.抗 CD20 嵌合型和人源化抗体在儿童特发性肾病综合征中的应用与不良反应的相关性。

Br J Clin Pharmacol. 2018 Jun;84(6):1238-1249. doi: 10.1111/bcp.13548. Epub 2018 Mar 25.

New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?新型及旧型抗 CD20 单克隆抗体治疗肾病综合征：我们已走到哪一步？

Front Immunol. 2022 Feb 11;13:805697. doi: 10.3389/fimmu.2022.805697. eCollection 2022.

Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.抗 CD20 治疗后小儿特发性肾病综合征免疫记忆持久受损。

Front Immunol. 2019 Jul 16;10:1653. doi: 10.3389/fimmu.2019.01653. eCollection 2019.

Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome.在儿童频复发/激素依赖型肾病综合征中，抗 CD20 治疗后复发风险和记忆 B 细胞再现与基线时的年龄和记忆 B 细胞相关。

Kidney Int. 2023 Sep;104(3):577-586. doi: 10.1016/j.kint.2023.06.013. Epub 2023 Jun 28.

Anti-Neu5Gc Antibodies do not Affect Response to Human or Chimeric Monoclonal Anti-CD20 Antibodies in Children with Nephrotic Syndrome.抗Neu5Gc抗体不影响肾病综合征患儿对人源或嵌合单克隆抗CD20抗体的反应。

J Am Soc Nephrol. 2022 Nov;33(11):1985-1987. doi: 10.1681/ASN.2022070755. Epub 2022 Aug 23.

Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature.孕期应用抗CD20疗法治疗肾病综合征：病例系列及文献综述

Ren Fail. 2025 Dec;47(1):2481201. doi: 10.1080/0886022X.2025.2481201. Epub 2025 Mar 27.

CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.基于液质联用技术的分析鉴定出，在特发性肾病综合征患儿中，与疾病复发相关的主要淋巴细胞亚群是类别转换 B 细胞。

Front Immunol. 2021 Sep 21;12:726428. doi: 10.3389/fimmu.2021.726428. eCollection 2021.

本文引用的文献

Risk factors and retreatment for relapse in childhood primary nephrotic syndrome treated with rituximab.利妥昔单抗治疗儿童原发性肾病综合征复发的危险因素及再次治疗

Pediatr Nephrol. 2025 May;40(5):1635-1644. doi: 10.1007/s00467-024-06622-z. Epub 2025 Jan 4.

Efficacy and Safety of Subcutaneous Rituximab in Idiopathic Nephrotic Syndrome.皮下注射利妥昔单抗治疗特发性肾病综合征的疗效与安全性

Kidney Int Rep. 2024 Aug 26;9(11):3332-3334. doi: 10.1016/j.ekir.2024.08.021. eCollection 2024 Nov.

Kidney Int. 2023 Sep;104(3):577-586. doi: 10.1016/j.kint.2023.06.013. Epub 2023 Jun 28.

Peripheral blood lymphocyte subsets in children with nephrotic syndrome: a retrospective analysis.肾病综合征患儿外周血淋巴细胞亚群：回顾性分析。

BMC Nephrol. 2023 Jan 10;24(1):7. doi: 10.1186/s12882-022-03015-y.

Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects.序贯利妥昔单抗治疗可维持肾病综合征的缓解，但不良反应风险较高。

Nephrol Dial Transplant. 2023 Mar 31;38(4):939-949. doi: 10.1093/ndt/gfac228.

Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.重复利妥昔单抗维持缓解治疗特发性儿童肾病综合征的长期疗效和安全性：一项国际研究。

J Am Soc Nephrol. 2022 Jun;33(6):1193-1207. doi: 10.1681/ASN.2021111472. Epub 2022 Mar 30.

New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?新型及旧型抗 CD20 单克隆抗体治疗肾病综合征：我们已走到哪一步？

Front Immunol. 2022 Feb 11;13:805697. doi: 10.3389/fimmu.2022.805697. eCollection 2022.

Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol.比较利妥昔单抗与吗替麦考酚酯治疗儿童及青年激素依赖型特发性肾病综合征的随机对照试验：研究方案。

BMJ Open. 2021 Nov 29;11(11):e052450. doi: 10.1136/bmjopen-2021-052450.

Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial.利妥昔单抗与低剂量霉酚酸酯治疗儿童和青年成人激素依赖型肾病综合征复发的随机临床试验

JAMA Pediatr. 2021 Jun 1;175(6):631-632. doi: 10.1001/jamapediatrics.2020.6150.

Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes.利妥昔单抗剂量和维持性免疫抑制在激素依赖型/频繁复发型肾病综合征中对治疗结果均有重要影响。

Kidney Int. 2020 Feb;97(2):393-401. doi: 10.1016/j.kint.2019.09.033. Epub 2019 Oct 31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验